Mylan price hikes: Congress calls on FDA for generic EpiPen submission info

By Dan Stanton contact

- Last updated on GMT

Mylan has hiked the price of its EpiPen up by 548% since 2007. Image: iStock/Roel Smart
Mylan has hiked the price of its EpiPen up by 548% since 2007. Image: iStock/Roel Smart

Related tags: Food and drug administration

Congress has asked the US FDA for information on EpiPen generic submissions and processes in light of a series of price hikes by drugmaker Mylan.

The pharma industry was hit with a pricing scandal earlier this month when it was revealed drugmaker Mylan had increased the price of the EpiPen – a life-saving allergy drug-device product – 17 times since 2007, or by a total of 548%.

The news came nine months after​ the industry fell afoul of the public and presidential candidates alike, when ‘pharma badboy’​ Martin Shkreli hiked the price of the off-patent toxoplasmosis drug darapim to $750 per pill.

While Mylan has since announced it is launching a generic, cheaper version of the Epipen, the US Committee on Energy and Commerce has laid out its concerns about the lack of generic competition in the epinephrine auto-injector space in a letter to Food and Drug Administration (FDA) commissioner Robert Califf (letter embedded below).

“We must ensure that federal law and regulations are best tailored to promote a competitive prescription drug market,”​ the Congress committee said, adding that some of the policy issues surrounding Mylan’s EpiPen intersect with FDA generic drug regulations.

“In 2012, the Energy and Commerce Committee lead the effort to pass the first generic drug user fee authorization (GDUFA) program. The goal of the legislation was to expedite the review of abbreviated new drug applications (ANDAs) and clear the backlog of applications at the agency.

“Improving the generic drug review process will promote competition and ultimately lower the cost of prescription drugs for America’s patients.”

Questioning guidance

As such, the Committee calls on the FDA to provide it with answers to a number of questions focused on the numbers of epinephrine generics that have been submitted for review, and the Agency’s prioritisation of such filings before September 9.

The Committee also questions guidance published in June 2013​ entitled: “Technical Considerations for Pen, Jet, and Related Injectors Intended for Use with Drugs and Biological Products,”​ and asks the Agency whether any follow up guidelines are set to be released discussing specific factors a company should consider when referencing EpiPen in an ANDA.

Evercore ISI analyst Umer Raffat told the FDA will respond to the information demand as the Agency is “always worried about safety.”

However, he said, “political pressure may play a role in improving the chances of generic approval this time,”​ and Teva and Antares Pharma will be likely to resubmit their generic EpiPen shortly after being knocked back earlier this year.

Related news

Show more

Related products

show more

How to resolve sticking issues in tablet production

How to resolve sticking issues in tablet production

I Holland Limited - Tabletting Science | 24-Jun-2019 | Case Study

Tablet sticking is one of the most common problems in tablet manufacture. Find out how I Holland used the TSAR scientific predictive model and expert tablet...

From Candidate to Clinic- European Capabilities

From Candidate to Clinic- European Capabilities

Catalent Pharma Solutions | 22-Oct-2018 | Technical / White Paper

Catalent’s Nottingham, UK facility focuses on early stage development of small molecule drug candidates from the bench to clinic. This facility offers...

Fill Release at the Right Time in the Right Place

Fill Release at the Right Time in the Right Place

Gelita AG | 19-Sep-2018 | Technical / White Paper

From rapid release in the stomach for e.g. analgesics to enteric release for fills with unpleasant aftertaste – GELITA delivers the respective gelatine...

Related suppliers

Follow us


View more